- Growth
by acquisition will be a priority following IPO spin-off, according to
CIIX CEO Warren Wang
- CIIX
reported significant revenue growth, with hemp and CBD sales increasing by
eight times year-over-year
- Industry
trend may indicate more hemp or marijuana being sourced from Columbia, or
Thailand and other Asian locations, moving forward
ChineseInvestors.com Inc. (OTCQB: CIIX) is currently
planning an IPO of wholly owned foreign enterprise CBD Biotech, according to
CEO Warren Wang. Wang said in a news release that the company hopes for a
Nasdaq IPO of CBD Biotech late in FY2019 or early the following year. CIIX
would then focus on identifying an acquisition target for further growth (http://ibn.fm/cL3A8).
Wang emphasized that the CBD IPO would be a priority,
followed by the acquisition search. CIIX sees CBD Biotech delivering higher CBD
product distribution in FY2019, both domestically and in China. Wang added that
the performance of the company’s financial services division in Q2 2019 was
strong, recording a 40 percent increase in revenues over the same period of the
prior year.
“As we leverage the momentum already in place, we look
forward to having an even stronger second half for FY 2019,” Wang said in a
news release (http://ibn.fm/O9Tv2).
Wang also discussed a possible future trend regarding
production and sourcing of hemp and marijuana from Asian nations such as
Thailand, as well as Columbia, due to cost savings as compared to relying on
U.S. and Canadian facilities. This trend impacts CIIX, because the company
sells hemp-based health products in China and the United States. CIIX also owns
and operates ChineseHempOil.com Inc.
Based in San Gabriel, California, CIIX is a diversified
company that offers its Chinese-speaking audience investment education through real-time
market commentary, video reports, podcasts and an online site. Financial
consulting services are provided to client companies as well.
For more information, visit the company’s website at www.ChineseInvestors.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from start-ups
to established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
